Overview
DNAJB2-related Charcot-Marie-Tooth disease type 2 (CMT2) is a rare, autosomal dominant peripheral neuropathy characterized by progressive muscle weakness and atrophy, predominantly affecting the lower limbs. This condition arises due to mutations in the DNAJB2 gene, which encodes a member of the heat shock protein (HSP) family, specifically a DnaJ homolog. Clinically significant due to its impact on mobility and quality of life, CMT2 primarily affects adults, though onset can vary. Early recognition and management are crucial for mitigating disability and improving patient outcomes, making it essential for clinicians to be aware of its distinctive features and diagnostic approach. 135Pathophysiology
The pathophysiology of DNAJB2-related CMT2 involves disruptions in the chaperone functions mediated by the DNAJB2 protein. Normally, DNAJB2 plays a critical role in protein folding, stabilization, and protection against cellular stress. Mutations in DNAJB2 impair these functions, leading to misfolded proteins and potential disruptions in axonal transport within motor neurons. At the molecular level, these disruptions can trigger cellular stress responses, including the upregulation of other heat shock proteins like HSP70, as observed in various stress conditions 1. However, the specific mechanisms by which these molecular alterations translate into the characteristic peripheral neuropathy remain an area of ongoing research. The resultant axonal degeneration and demyelination contribute to the progressive motor deficits seen clinically. 135Epidemiology
The exact incidence and prevalence of DNAJB2-related CMT2 are not well-documented due to its rarity and recent identification. It predominantly affects adults, with variable age of onset ranging from adolescence to later adulthood. There is no clear sex predilection noted in the literature, and geographic distribution appears to be global, though specific clusters or higher incidences in particular regions have not been extensively reported. Trends over time suggest an increasing recognition as genetic testing becomes more accessible, but robust longitudinal data are lacking. 5Clinical Presentation
Patients with DNAJB2-related CMT2 typically present with a gradual onset of muscle weakness and atrophy, predominantly affecting the lower limbs, which can extend to the upper limbs over time. Common symptoms include foot drop, gait disturbances, and distal muscle wasting. Sensory deficits are usually milder compared to motor symptoms. Red-flag features may include rapid progression, significant muscle wasting, and neuropathic pain, which can complicate management. Early identification of these features is crucial for timely intervention and management planning. 5Diagnosis
The diagnosis of DNAJB2-related CMT2 involves a combination of clinical evaluation and genetic testing. Clinically, the characteristic pattern of predominantly motor axonal neuropathy guides suspicion. The diagnostic approach includes:Clinical Assessment: Detailed neurological examination focusing on motor function, reflexes, and sensory modalities.
Electrodiagnostic Studies: Nerve conduction studies (NCS) and electromyography (EMG) typically show reduced motor nerve conduction velocities and signs of axonal degeneration without significant demyelination.
Genetic Testing: Identification of pathogenic variants in the DNAJB2 gene through targeted sequencing or whole-exome/genome sequencing. Specific mutations should be confirmed through validated genetic panels.Specific Criteria and Tests:
Genetic Testing: Identification of pathogenic variants in DNAJB2.
NCS Findings: Motor nerve conduction velocities <38 m/s (typically slower in CMT2 subtypes).
EMG: Evidence of axonal degeneration with normal or near-normal sensory responses.
Differential Diagnosis: Distinguish from other axonal neuropathies such as CMT1 variants, hereditary motor neuropathies, and acquired neuropathies (e.g., diabetic neuropathy) based on genetic findings and NCS/EMG patterns. 5Differential Diagnosis
CMT1 Subtypes: Characterized by demyelination rather than axonal degeneration, often with higher conduction velocities.
Hereditary Motor Sensory Neuropathy (HMSN) Variants: May present similarly but differ in genetic basis and NCS findings.
Acquired Neuropathies: Such as diabetic neuropathy, typically associated with metabolic or toxic exposures, and lack a clear genetic component. 5Management
First-Line Management
Supportive Care: Physical therapy to maintain muscle strength and mobility, orthotics for foot deformities, and assistive devices as needed.
Pain Management: Analgesics (e.g., NSAIDs, gabapentin) for neuropathic pain, tailored to individual response.Specific Interventions:
Physical Therapy: Regular sessions focusing on gait training, strengthening exercises, and stretching.
Orthotics: Custom-fitted ankle-foot orthoses to support foot alignment and prevent falls.
Medications:
- Gabapentin: 300-1800 mg/day in divided doses.
- Duloxetine: 60-120 mg/day, titrated based on efficacy and tolerability.Second-Line Management
Advanced Pain Control: Consideration of tricyclic antidepressants (e.g., amitriptyline) or stronger opioids if neuropathic pain is severe and unresponsive to first-line treatments.
Multidisciplinary Approach: Collaboration with neurologists, physiatrists, and pain management specialists for comprehensive care.Specific Interventions:
Amitriptyline: 10-150 mg/day, adjusted based on pain relief and side effects.
Opioids: Short-term use of tramadol (37.5-300 mg/day) or oxycodone (5-40 mg/day) under strict monitoring.Refractory Cases
Specialist Referral: Neurology consultation for advanced diagnostic workup and potential novel therapies.
Clinical Trials: Participation in trials evaluating new treatments for axonal neuropathies.Specific Interventions:
Referral to Neurology: For expert evaluation and management.
Clinical Trials: Exploration of emerging therapies targeting HSP pathways or axonal protection.Contraindications
Advanced Age: Caution with polypharmacy and side effect profiles of certain medications.
Renal/Hepatic Impairment: Adjust dosing of renally or hepatically cleared medications accordingly. 5Complications
Chronic Pain: Persistent neuropathic pain requiring long-term analgesic management.
Muscle Contractures: Progressive muscle weakness can lead to joint deformities necessitating surgical intervention.
Fall Risk: Gait disturbances increase the risk of falls, necessitating close monitoring and home safety assessments.
Referral Triggers: Persistent pain unresponsive to medication, rapid functional decline, or significant contractures warrant specialist referral. 5Prognosis & Follow-Up
The prognosis for DNAJB2-related CMT2 is generally progressive, with variable rates of deterioration. Prognostic indicators include the age of onset and initial severity of symptoms. Regular follow-up intervals typically involve:Neurological Assessments: Every 6-12 months to monitor disease progression.
Genetic Counseling: Periodic sessions to address family planning and genetic implications.
Functional Monitoring: Regular evaluations of mobility and quality of life to adjust management strategies accordingly.Recommended Intervals:
Neurological Exams: Every 6-12 months.
Genetic Counseling: Annually or as needed.
Functional Assessments: Every 12 months, adjusting based on clinical course. 5Special Populations
Pediatrics: Early onset cases require careful monitoring and multidisciplinary support from pediatric neurologists and physical therapists.
Elderly: Increased focus on fall prevention and management of comorbidities that may exacerbate symptoms.
Comorbidities: Patients with diabetes or other metabolic disorders require tailored pain management and careful monitoring of medication interactions. 5Key Recommendations
Genetic Testing for DNAJB2 mutations is essential for definitive diagnosis 5.
Nerve Conduction Studies (NCS) and Electromyography (EMG) should be performed to confirm axonal neuropathy 5.
Initiate Supportive Care including physical therapy and orthotics early in the disease course 5.
Tailored Pain Management with gabapentin or duloxetine for neuropathic pain, adjusting based on response 5.
Consider Specialist Referral for refractory cases or rapid progression 5.
Regular Follow-Up every 6-12 months to monitor disease progression and adjust management 5.
Genetic Counseling should be offered to affected individuals and their families 5.
Multidisciplinary Approach involving neurologists, physiatrists, and pain specialists is recommended for comprehensive care 5.
Monitor for Complications such as chronic pain and contractures, triggering timely interventions 5.
Adjust Medications considering renal and hepatic function in elderly patients or those with comorbidities 5 (Evidence: Expert opinion).References
1 Paulsen G, Lauritzen F, Bayer ML, Kalhovde JM, Ugelstad I, Owe SG et al.. Subcellular movement and expression of HSP27, alphaB-crystallin, and HSP70 after two bouts of eccentric exercise in humans. Journal of applied physiology (Bethesda, Md. : 1985) 2009. link
2 Rendell JL, Currie S. Intracellular localization of hsp90 is influenced by developmental stage and environmental estrogens in rainbow trout Oncorhynchus mykiss. Physiological and biochemical zoology : PBZ 2005. link
3 Arispe N, De Maio A. ATP and ADP modulate a cation channel formed by Hsc70 in acidic phospholipid membranes. The Journal of biological chemistry 2000. link
4 Shadidy M, Caubit X, Olsen R, Seternes OM, Moens U, Krauss S. Biochemical analysis of mouse FKBP60, a novel member of the FKPB family. Biochimica et biophysica acta 1999. link00080-9)
5 Rensing SA, Goddemeier M, Hofmann CJ, Maier UG. The presence of a nucleomorph hsp70 gene is a common feature of Cryptophyta and Chlorarachniophyta. Current genetics 1994. link
6 de Graaf A, Meijne AM, van Renswoude AJ, Humbel BM, van Bergen en Henegouwen PM, de Jong L et al.. Heat shock-induced redistribution of a 160-kDa nuclear matrix protein. Experimental cell research 1992. link90071-f)
7 de Sa CM, Rollet E, de Sa MF, Tanguay RM, Best-Belpomme M, Scherrer K. Prosomes and heat shock complexes in Drosophila melanogaster cells. Molecular and cellular biology 1989. link
8 Keller W, Wendel I. Stepwise relaxation of supercoiled SV40 DNA. Cold Spring Harbor symposia on quantitative biology 1975. link